S3845 HCPCS Level II code: Genetic testing for alpha-thalassemia
S3845 is the HCPCS code for “Genetic testing for alpha-thalassemia” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
S3845Genetic testing for alpha-thalassemia
Short description: Gene test alpha-thalassemia
HCPCS · United States
Medicare details
The indicators CMS publishes with S3845 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Not payable by Medicare
- Medicare pricing
- Service not separately priced by Part B (e.g., services not covered, bundled, used by Part A only, etc.)
- Type of service
- Other medical items or services
- BETOS category
- Undefined codes
- Added
- Jul 1, 2003
Where S3845 sits
- 1S codesTemporary national codes (non-Medicare)
- 2Active code S3845Genetic testing for alpha-thalassemia
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code S3845 mean?
S3845 is the HCPCS code for “Genetic testing for alpha-thalassemia” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover S3845?
CMS lists S3845’s Medicare coverage as “Not payable by Medicare” and its pricing as “Service not separately priced by Part B (e.g., services not covered, bundled, used by Part A only, etc.)”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside S3845
All S codesS3722Dose optimization by area under the curve (auc) analysis, for infusional 5-fluorouracilS3800Genetic testing for amyotrophic lateral sclerosis (als)S3840Dna analysis for germline mutations of the ret proto-oncogene for susceptibility to multiple endocrine neoplasia type 2S3841Genetic testing for retinoblastomaS3842Genetic testing for von hippel-lindau diseaseS3844Dna analysis of the connexin 26 gene (gjb2) for susceptibility to congenital, profound deafnessS3846Genetic testing for hemoglobin e beta-thalassemiaS3849Genetic testing for niemann-pick diseaseS3850Genetic testing for sickle cell anemiaS3852Dna analysis for apoe epsilon 4 allele for susceptibility to alzheimer's diseaseS3853Genetic testing for myotonic muscular dystrophyS3854Gene expression profiling panel for use in the management of breast cancer treatment